Healthcare of Ontario Pension Plan Trust Fund Acquires Shares of 224,300 Axonics, Inc. (NASDAQ:AXNX)

Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Axonics, Inc. (NASDAQ:AXNX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 224,300 shares of the company's stock, valued at approximately $15,080,000. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.44% of Axonics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AXNX. KRYGER CAPITAL Ltd purchased a new position in shares of Axonics in the first quarter worth approximately $65,211,000. Magnetar Financial LLC grew its position in Axonics by 218.3% during the 1st quarter. Magnetar Financial LLC now owns 1,146,019 shares of the company's stock worth $79,041,000 after purchasing an additional 785,981 shares in the last quarter. Absolute Gestao de Investimentos Ltda. acquired a new stake in Axonics during the 2nd quarter valued at $32,681,000. Alpine Associates Management Inc. lifted its holdings in shares of Axonics by 16.2% in the second quarter. Alpine Associates Management Inc. now owns 2,108,871 shares of the company's stock valued at $141,779,000 after purchasing an additional 294,100 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new stake in shares of Axonics in the first quarter valued at $16,573,000. Institutional investors and hedge funds own 99.48% of the company's stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a "hold" rating on shares of Axonics in a research note on Monday, August 5th. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $69.57.

Axonics Price Performance

AXNX stock traded down $0.01 during midday trading on Friday, reaching $69.62. The company had a trading volume of 318,084 shares, compared to its average volume of 729,589. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -217.59 and a beta of 0.81. Axonics, Inc. has a 1-year low of $48.30 and a 1-year high of $69.91. The stock has a 50 day moving average price of $68.93 and a 200-day moving average price of $68.05.

Axonics (NASDAQ:AXNX - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.03. The business had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. Axonics's quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.15) EPS. As a group, research analysts anticipate that Axonics, Inc. will post 0.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Kari Leigh Keese sold 2,961 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares in the company, valued at approximately $2,801,526.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.85% of the company's stock.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.